Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Supervisors info:
Τσιτσιλώνη Ουρανία, Καθηγήτρια, Τμήμα Βιολογίας, ΕΚΠΑ
Τέρπος Ευάγγελος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ανδρεάδου Ιωάννα, Καθηγήτρια, Τμήμα Φαρμακευτικής, ΕΚΠΑ
Original Title:
Θεραπευτική χρήση του συστήματος CRISPR/Cas: Ανασκόπηση βιβλιογραφίας Κλινικών μελετών
Translated title:
Therapeutic use of the CRISPR/Cas system: A literature review of clinical studies
Summary:
The current therapeutic agents for cancer treatment have substantial drawbacks,
including low success rates and high toxicity levels, despite the progress made in
immunotherapy and chemotherapy. Furthermore, the efficacy of ongoing
multi-targeted therapies is limited to a limited number of carcinogenic pathways. This
is due to the ongoing emergence and evolution of mutations in proto-oncogenes and
tumor-suppressive genes.
In order to rectify causative mutations with minimal toxicity, CRISPR/Cas9 is
employed as a precise gene-editing instrument. Furthermore, it is utilized as an
adjuvant to immunotherapy to improve the immune response. The CRISPR/Cas9
technology has a number of significant drawbacks that must be taken into account.
One of these is the potential for off-target mutations, which can result in unintended
modifications to DNA that are not specifically targeted.Furthermore, the absence of a
distinct scientific consensus on risk evaluation and ethical concerns are also factors to
take into account.
At present, scientists are conducting experiments to enhance the precision of genome
editing and to induce a more potent immune response against malignancies.
Furthermore, the CRISPR/Cas9 system is currently being employed in clinical trials
to precisely modify the genomes of immune cells.
In an effort to mitigate the constraints of this gene-editing methodology, scientists
have lately devised error-free in vitro systems.
Main subject category:
Health Sciences
Keywords:
CRISPR/Cas , Cancer, Clinical trials
Number of references:
158
File:
File access is restricted only to the intranet of UoA.
Frousiou_Georgia_MSc.pdf.pdf
3 MB
File access is restricted only to the intranet of UoA.
